Table 4.
Associations Between Total Number of Intravitreal Ranibizumab Injections and Clinical Factors at Baseline and 12 Months after Initial Treatment.
| R | P value | |
|---|---|---|
| Baseline | ||
| Age | 0.101 | 0.450 |
| LogMAR visual acuity | 0.231 | 0.083 |
| Foveal thickness | 0.164 | 0.223 |
| Total NPA | 0.006 | 0.965 |
| Central macular NPA in SCP | 0.133 | 0.555 |
| Central macular NPA in DCP | 0.120 | 0.595 |
| 12 months after initial treatment | ||
| LogMAR visual acuity | 0.037 | 0.781 |
| Total NPA | 0.061 | 0.689 |
| Central macular NPA in SCP | 0.044 | 0.787 |
| Central macular NPA in DCP | 0.060 | 0.713 |
LogMAR = logarithm of the minimum angle of resolution; NPA = retinal nonperfusion area; SCP = superficial capillary plexus; DCP = deep capillary plexus.